Hot Deals:
adtech 75.00 (-6.25 %) agarwal bolts 1,200.00 (0.00 %) amol minechem 601.00 (0.17 %) anand i-power 20.00 anglo french drugs 745.00 (-0.67 %) apl metals 41.00 (-8.89 %) arkfin investments 50.00 arohan 145.00 (3.57 %) assam carbon 200.00 (2.56 %) atlas copco 10,000.00 (1.01 %) auckland international 129.00 (-0.77 %) av thomas 16,800.00 (0.00 %) axles 500.00 (-1.96 %) balmer lawrie 202.00 (1.00 %) bharat hotels 300.00 (3.45 %) bima mandi 235.00 (-2.08 %) bira 595.00 (-0.83 %) boat 1,330.00 (0.76 %) c & s electric 600.00 (1.69 %) cable corporation 13.00 (-0.76 %) capgemini 11,400.00 (-0.87 %) care health 182.00 (1.11 %) carrier aircon 535.00 (1.90 %) cial 275.00 (1.85 %) csk 178.00 (1.71 %) dalmia refract 155.00 (1.97 %) dfm foods 467.00 dsp merrill lynch 1,000.00 east india pharma 39.00 (-2.50 %) eaton fluid 425.00 (2.66 %) electronica plastic 2,100.00 (-0.99 %) elgi ultra 400.00 elofic 2,070.00 (-1.43 %) esl steel 41.00 (2.50 %) fincare business 72.00 (2.86 %) fincare sfbl 202.00 (1.00 %) finopaytech 155.00 (-3.13 %) flipkart india 231,001.00 (0.00 %) frick india 14,000.00 (3.70 %) gkn driveline 1,300.00 (4.00 %) go digit general insurance ltd 354.00 (1.14 %) godavari bio 71.00 (1.43 %) hdb financial 910.00 (1.68 %) hdfc ergo 370.00 (1.70 %) hdfc securities 10,750.00 (0.47 %) hella india 810.00 (1.25 %) hero fincorp 1,600.00 (0.63 %) hexaware 860.00 (1.18 %) hicks 1,450.00 (2.11 %) hira ferro 155.00 (3.33 %) honeywell electrical 4,500.00 (2.27 %) ikf finance 215.00 (2.38 %) incred financial 109.00 (3.81 %) incred holdings 150.00 (3.45 %) india carbon 1,170.00 (1.74 %) india exposition 135.00 (-0.74 %) indian potash 3,000.00 (-1.64 %) indo alusys 25.75 (-0.96 %) indofil 790.00 (1.28 %) infinite computer 405.00 (1.25 %) inkel 21.00 (3.96 %) ixigo 144.00 (-0.69 %) jana small finance bank 75.00 kel 625.00 (1.63 %) kial 122.00 (-2.40 %) klm axiva 15.00 (-1.32 %) kurlon limited 650.00 (4.00 %) lava 71.00 (-1.39 %) mahindra rural mrhfl 100.00 manipal housing 72.50 (0.69 %) manjushree technopack 1,150.00 (2.68 %) martin & harris 1,000.00 (1.01 %) merino 3,300.00 (-1.49 %) minosha 282.00 (0.71 %) mitsubishi heavy 207.00 (-0.48 %) mkcl 430.00 (1.18 %) mobikwik 570.00 (-0.87 %) mohan meakin 1,900.00 (-1.04 %) mohfl 13.25 (-0.38 %) msei 1.20 (-1.64 %) msil 36.00 (-10.00 %) nayara energy 415.00 (1.22 %) nayara energy ncd 285.00 (1.79 %) ncdex 275.00 ncl buildtek 255.00 (-1.16 %) ncl holdings 71.00 (1.43 %) nsdl 700.00 nse 4,500.00 (-0.99 %) orbis financial 250.00 (-1.96 %) oswal minerals 60.10 (-1.48 %) otis 3,770.00 (0.53 %) oyo 57.00 (-1.72 %) panasonic appliances 211.00 (0.48 %) paymate india 530.00 (1.92 %) pharmeasy 10.00 (1.01 %) pharmed limited 480.00 (2.13 %) philips domestic 600.00 (1.69 %) philips india 950.00 (3.26 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 300.00 (-1.64 %) rapido 16,650.00 (0.03 %) rasoi 31,500.00 (0.32 %) reliance gic 480.00 (0.84 %) resins plastics 415.00 (-1.89 %) ring plus aqua 425.00 (4.94 %) rrl 1,275.00 (2.00 %) sab miller 380.00 (1.33 %) sbi amc 1,600.00 (0.95 %) sbi general insurance 600.00 (3.45 %) scottish assam 440.00 (-1.35 %) shriram life 261.00 (0.38 %) sigachi laboratories 36.00 (-2.70 %) signify 1,300.00 (-0.91 %) smile microfinance 54.00 (3.85 %) sportskeeda 3,303.00 sterlite power 510.00 (2.00 %) studds 970.00 (-1.02 %) svsml 310.00 (-3.13 %) swiggy 350.00 (-1.41 %) t stanes 755.00 (2.72 %) tata capital 840.00 (1.82 %) teesta agro 77.00 (-6.21 %) trl krosaki 1,300.00 (-1.89 %) utkarsh coreinvest 310.00 (-1.59 %) vadilal dairy 10.00 vikram solar 170.00 (-2.86 %) waree energies 1,940.00 (-0.51 %)
×

Arch Pharma Annual Reports, Balance Sheet and Financials

Arch PharmaLabs Limited (Arch Pharmalabs) Return Comparision with Primex 40 Index

Periods 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years All Time
Primex-40
Arch PharmaLabs Limited

Balance Sheet of Arch Pharma Labs Limited (In Rs. Crore)

Particulars

31st March 2022

31st March 2021

31st March 2020

Assets

     

Non-Current Assets:

 

 

 

Fixed Assets

912.7

958.56

1,013.25

Property, Plant, and Equipment 

876.27

923.54

976.72

Capital Work in Progress 

8.52

4.38

21.63

Intangible Assets 

10.07

12.68

14.9

Intangible Assets under Development

17.84

17.96

0

Total Reported Non-current Assets

970.21

1,020.68

1,220.36

Current Assets:

 

 

 

 Inventories 

698.91

772.04

832.58

Financial Assets :

 

 

 

Trade Receivables 

314.03

274.34

439.39

Total Current Assets

1,347.98

1,341.62

1,889.02

Total Assets

2,318.19

2,362.30

3,109.38

Equity And Liabilities

 

 

 

Equity

     

Share Capital 

151.92

151.92

151.92

Minority Interest

2.93

3.39

3.39

Total Equity

606.72

232.6

-1,603.52

Non-Current Liabilities:

 

 

 

Long Term Borrowings 

682.43

1,063.27

3,070.84

Total Reported Non-current Liabilities

682.43

1,063.27

3,070.84

Current Liabilities:

 

 

 

Short Term Borrowings 

187.47

168.59

113.12

Trade Payables 

337.03

456.11

475.48

Total Current Liabilities

1,029.04

1,066.43

1,642.06

Total Equity and Liabilities

2,318.19

2,362.30

3,109.38

Profit & Loss Statement of Arch Pharma Labs Limited (In Rs. Crore)

Particulars

2022

2021

2020

Revenue From Operations 

1,308.98

706.01

632.29

Other Income 

5.11

92.57

19.22

Total Revenue

1,314.09

798.58

651.5

EXPENSES:

 

 

 

Cost of Material Consumed 

1,052.31

444.47

563.08

Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade 

-68.22

21.14

-86.06

Employee Benefits / Salaries & Other Staff Cost 

74.88

74.12

61.63

Finance Cost 

98.33

230.84

204.67

Depreciation and Amortization 

25.06

27.8

30.3

Other Expenses 

73.2

891.67

55.21

Total Expenses

1,255.56

1,690.03

828.83

Profit Before Exceptional Items and Tax

58.53

-891.45

-177.32

Exceptional Items Before Tax 

0

2,760.89

17.13

Profit Before Extraordinary Items and Tax

58.53

1,869.44

-160.19

Profit Before Tax

58.53

1,869.44

-160.19

Tax Expenses

-0.19

0

-0.69

Current Tax

-0.19

0

-0.69

Profit After Tax

58.71

1,869.44

-159.5

Earnings Per Share - Basic

3.41

123.05

-10.5

Earnings Per Share - Diluted

3.41

123.05

-10.5

Arch Pharma Labs Limited Cash Flow Statement for the last three years (In Rs. Crore)

Particulars

31st March 2022

31st March 2021

31st March 2020

Cash Flow Summary

 

 

 

Cash and Cash Equivalents at the beginning of the year

3.28

2.77

4.19

Net Cash from Operating Activities 

115.33

278.33

181.26

Net Profit before Tax & Extraordinary Items

58.53

1869.44

-160.19

Depreciation

25.06

27.8

30.3

Interest (Net)

98.33

230.84

210.83

Others

-1.28

-1973.83

-23.29

Total Adjustments (PBT & Extraordinary Items)

122.12

-1715.19

218.99

Op. Profit before Working Capital Changes

180.65

154.25

58.8

Trade & other receivables

-43.43

-11.95

150.22

Inventories

73.14

29.97

-102.87

Others

-94.84

106.07

74.42

Total (OP before Working Capital Changes)

-65.13

124.08

121.77

Cash Generated from/(used in) Operations

115.52

278.33

180.57

Direct Taxes Paid

-0.19

0

0.69

Total-others

-0.19

0

0.69

Cash Flow before Extraordinary Items

115.33

278.33

181.26

Net Cash Used in Investing Activities 

-10.68

-7.89

-7.55

Purchased Fixed Assets

-15.67

-7.87

-7.77

Interest Received

5.02

0.18

0.17

Others

-0.02

-0.2

0

Net Cash Used in Financing Activities 

-105.16

-269.93

-175.14

Proceed from 0ther Long Term Borrowings

0

0

29.62

Of the Long-Term Borrowings

-6.83

-39.1

0

Interest Paid

-98.33

-230.84

-204.67

Net Cash Used in Financing Activities

-105.16

-269.93

-175.14

Net Inc/(Dec) in Cash and Cash Equivalent

-0.51

0.51

-1.43

Cash and Cash Equivalents at End of the year

2.77

3.28

2.77

Summary of Arch Pharma Labs Limited Consolidated Cash Flow Statement:

1. Cash Flow from Operating Activities:

   - Net cash from operating activities was positive, indicating cash inflow, amounting to Rs. 115.33 crore in the year ending March 31, 2022, Rs. 278.33 crore in the year ending March 31, 2021, and Rs. 181.26 crore in the year ending March 31, 2020.

   - Net profit before tax and extraordinary items was positive, amounting to Rs. 58.53 crore in the year ending March 31, 2022, Rs. 1869.44 crore in the year ending March 31, 2021, and negative Rs. -160.19 crore in the year ending March 31, 2020.

   - Depreciation expenses and net interest expenses were incurred and adjusted for in each year.

   - Other adjustments were made, including items related to extraordinary items and operational income.

   - Cash generated from operations before working capital changes was positive, amounting to Rs. 180.65 crore in the year ending March 31, 2022, Rs. 154.25 crore in the year ending March 31, 2021, and Rs. 58.8 crore in the year ending March 31, 2020.

   - Working capital changes, including trade receivables, inventories, and other items, contributed to the cash flow from operating activities.

2. Cash Flow from Investing Activities:

   - Net cash used in investing activities was negative, indicating cash outflow, amounting to Rs. -10.68 crore in the year ending March 31, 2022, Rs. -7.89 crore in the year ending March 31, 2021, and Rs. -7.55 crore in the year ending March 31, 2020.

   - Activities include the purchase of fixed assets and other investing activities.

3. Cash Flow from Financing Activities:

   - Net cash used in financing activities was negative, indicating cash outflow, amounting to Rs. -105.16 crore in the year ending March 31, 2022, Rs. -269.93 crore in the year ending March 31, 2021, and Rs. -175.14 crore in the year ending March 31, 2020.

   - Activities include proceeds from other long-term borrowings, repayment of long-term borrowings, interest payments, and other financing activities.

4. Net Increase/ (Decrease) in Cash and Cash Equivalents:

   - There was a decrease in cash and cash equivalents of Rs. -0.51 crore in the year ending March 31, 2022, an increase of Rs. 0.51 crore in the year ending March 31, 2021, and a decrease of Rs. -1.43 crore in the year ending March 31, 2020.

   - Cash and cash equivalents at the beginning of the year were Rs. 3.28 crore in the year ending March 31, 2022, Rs. 2.77 crore in the year ending March 31, 2021, and Rs. 4.19 crore in the year ending March 31, 2020.

   - Cash and cash equivalents at the end of the year were Rs. 2.77 crore in the year ending March 31, 2022, Rs. 3.28 crore in the year ending March 31, 2021, and Rs. 2.77 crore in the year ending March 31, 2020.

Funds Flow Statement of Arch Pharma Labs Limited (In Rs. Crore)

Particulars

Mar-22

Mar-21

Mar-20

Sources of funds

 

 

 

Cash profit

117.14

2,768.45

0

Increase in equity

0

151.92

0

Increase in other net worth

350.05

0

0

Increase in loan funds

0

1,231.86

29.52

Decrease in gross block

0

0

2.15

Decrease in investments

6.82

0

0.05

Decrease in working capital

0

0

106.06

Others

2.29

0

0

Total Inflow

476.3

4,152.23

137.78

Application of funds

 

 

 

Cash loss

0

0

103.69

Decrease in net worth

0

2,384.87

0

Decrease in loan funds

361.96

0

0

Increase in gross block

14.86

1,255.15

0

Increase in investments

0

22.38

0

Increase in working capital

64.84

483.52

0

Others

2.29

0

0

Total Outflow

475.83

4,155.63

137.79

Key Financial Ratios of Arch Pharma Labs Limited

Particulars

2022

2021

2020

Key Ratios

 

 

 

Current Ratio

1.28

1.26

1.36

Turnover Ratios

 

 

 

Fixed Assets Turnover Ratio

1.04

0.57

0.53

Inventory Turnover Ratio

1.78

0.91

0.81

Debtors Turnover Ratio

4.45

2.57

1.23

Total Asset Turnover Ratio

0.89

0.48

0.29

Interest Cover Ratio

1.6

-2.86

0.22

PBIDTM (%)

13.9

-89.6

11.83

PBITM (%)

11.98

-93.54

7.03

PBDTM (%)

6.39

-122.3

-20.54

CPM (%)

6.4

-122.3

-20.43

APATM (%)

4.49

-126.24

-25.23

ROCE (%)

8.95

-34.17

0

RONW (%)

8.38

-127.16

0

Summary of Key Financial Ratios of Arch Pharma Labs:

1. Current Ratio:

The current ratio, measuring the company 's ability to meet short-term obligations, has remained relatively stable over the three years, with values of 1.28 in 2022, 1.26 in 2021, and 1.36 in 2020. The company appears to have enough current assets to cover its short-term liabilities, suggesting a satisfactory liquidity position.

2. Turnover Ratios:

- Fixed Assets Turnover Ratio: The fixed assets turnover ratio indicates how efficiently the company utilizes its fixed assets to generate revenue. Arch Pharma Labs has shown a steady improvement in this ratio, with values of 1.04 in 2022, 0.57 in 2021, and 0.53 in 2020. The increasing trend indicates better utilization of fixed assets over the years.

- Inventory Turnover Ratio: The inventory turnover ratio reflects how efficiently the company manages its inventory. Arch Pharma Labs has improved its inventory turnover significantly, with values of 1.78 in 2022, 0.91 in 2021, and 0.81 in 2020. This suggests improved inventory management and potentially reduced carrying costs.

- Debtors Turnover Ratio: The debtors turnover ratio indicates how efficiently the company collects cash from its debtors. Arch Pharma Labs has demonstrated consistent improvement in this area, with values of 4.45 in 2022, 2.57 in 2021, and 1.23 in 2020. The increasing trend suggests enhanced credit management and collection efficiency.

- Total Asset Turnover Ratio: The total asset turnover ratio measures the company 's ability to generate revenue from its total assets. Arch Pharma Labs has shown a considerable improvement in this ratio, with values of 0.89 in 2022, 0.48 in 2021, and 0.29 in 2020. This indicates better utilization of its assets to generate revenue.

3. Interest Cover Ratio:

The interest cover ratio evaluates the company 's ability to cover its interest expenses with its operating profit. In 2022, the interest cover ratio stands at 1.6, compared to -2.86 in 2021 and 0.22 in 2020. While it has improved, the ratio is still relatively low, suggesting the company may face challenges in covering its interest expenses.

4. Profitability Ratios:

- PBIDTM (%): The PBIDTM (Profit Before Interest, Depreciation, and Tax Margin) has significantly improved in 2022, reaching 13.9% from -89.6% in 2021 and 11.83% in 2020. This indicates a substantial improvement in the company 's operational profitability, which is a positive sign.

- PBITM (%): The PBITM (Profit Before Interest and Tax Margin) has also seen notable improvement, with values of 11.98% in 2022, -93.54% in 2021, and 7.03% in 2020. This suggests the company 's profitability has significantly improved before considering interest and taxes.

- PBDTM (%): The PBDTM (Profit Before Depreciation and Tax Margin) shows improvement, with values of 6.39% in 2022, -122.3% in 2021, and -20.54% in 2020. This indicates improved profitability after considering depreciation expenses.

5. Return Ratios:

Both the Return on Capital Employed (ROCE) and the Return on Net Worth (RONW) have shown improvement in 2022 compared to previous years. The ROCE stands at 8.95% in 2022, compared to -34.17% in 2021 and 0% in 2020. The RONW stands at 8.38% in 2022, compared to -127.16% in 2021 and 0% in 2020. These positive figures reflect an improvement in the company 's ability to generate returns for its capital and shareholders.

Overall, the financial ratios of Arch Pharma Labs Limited indicate significant improvements in profitability and operational efficiency in 2022 compared to previous years. However, the company still faces challenges in covering interest expenses and may need to sustain its positive momentum to achieve long-term financial stability. Investors and stakeholders should carefully analyze these ratios to make informed decisions about their involvement with the company.

Arch Pharma Labs Dividend History

Particulars

2022

2021

2020

2019

Dividend (final + interim) (In Rs.)

Nil

Nil

Nil

Nil

Arch Pharma Recent Performance

  • Revenue from Operations increased 85.40% from Rs. 706.01 Crore in FY 2021 to Rs. 1308.98 Crore in FY 2022.

  • Total borrowings of the company decreased from Rs. 1231.86 Crore in FY 2021 to Rs. 869.90 Crore in FY 2022.
  • The Finance cost of the company decreased by 57.40% from Rs. 230.84 Crore to Rs. 98.33 Crore.
  • Profit after tax of the company stood at Rs. 58.71 Crore in FY 2022 against a Profit after tax of Rs. 1869.44 Crore in FY 2021, showing a fall of 96.55%.
  • For FY 2022, the company’s EPS was Rs. 3.41.
  • The Current Ratio of the company as of 31st March 2022 is 1.28.
  • The book value per share of the company as of 31st March 2022 is Rs. 39.93.

 

Annual Report

Arch PharmaLabs Annual Report 2021-22

Download

Arch PharmaLabs Annual Report 2020-21

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha